Study of AMX-883 for leukemia and MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called AMX-883 for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. It studies the drug alone and combined with another medicine to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that did not respond to treatment or came back, or high-risk MDS with bone marrow blasts between 10-19%
- You can care for yourself (ECOG performance status 0-2)
- You have had a break from previous cancer therapies as required
- Your kidneys and liver are working well enough
- You agree to use effective birth control (no sperm donation for at least 120 days)
- You do not have certain serious heart conditions or other active cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
This trial tests a new drug, S241656, alone or with other treatments, for people with specific types of blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments or have come back.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.